Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Parkinson’s Foundation Welcomes Two New Board Members

Peter Goldman and Joshua Raskin Join Board of Directors

NEW YORK & MIAMI — The Parkinson’s Foundation today announced the election of Chicago entrepreneur Peter Goldman and New York financial analyst Joshua Raskin to its Board of Directors.

“Peter and Joshua bring valuable business and philanthropic experience that will further advance the Parkinson’s Foundation’s mission to serve the one million Americans and ten million people worldwide living with this disease,” said John W. Kozyak, Esq., Chairman of the Board of the Parkinson’s Foundation.

Peter Goldman

Goldman is managing partner of Lakeshore Sport & Fitness in Chicago, which owns and operates businesses in the Chicago area focused on hospitality, health and wellness. Before becoming an entrepreneur, Goldman worked for Sam Zell in real estate investing and McKinsey & Company as a management consultant. He has served on several non-profit boards including the Auxiliary Board of the Art Institute of Chicago, where he was a vice president and created a new annual signature fundraising event. 

“I am excited to join the Parkinson’s Foundation board at this critical time,” Goldman said. “The Parkinson’s Foundation’s mission to make life better for people with Parkinson’s is more urgent than ever with 60,000 new cases being diagnosed every year.”

Joshua Raskin

For the past 18 years, Raskin has served as managing director at Barclay's Capital, where he coordinates coverage of the healthcare services sector in the equity research department. Prior to this, he was a managing director at Lehman Brothers for nine years. In 2017, Raskin formed Nephron Research, an independent research boutique focused on healthcare. He has a personal connection to Parkinson’s in his immediate family.

“The fight against Parkinson’s disease and the mission of finding a cure are of deep importance to me, particularly in light of my family history,” Raskin said. “I remain committed to the Parkinson’s community in my new role on the Parkinson’s Foundation board of directors.”

A complete list of the Parkinson’s Foundation’s Board of Directors is available at www.parkinson.org/board.

About the Parkinson’s Foundation

The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience, and passion of our global Parkinson’s community. For more information, visit www.parkinson.org or call (800) 4PD-INFO (473-4636).

About Parkinson’s Disease

Affecting an estimated one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety A feeling of nervousness, worried thoughts and physical distress.). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the United States alone.

Tuesday, October 24, 2017
The Parkinson’s Foundation 2018 Gala in New York City Tuesday, May 8, 2018
Monday, May 14, 2018

The Parkinson’s Foundation 2018 Gala was held at Cipriani 25 Broadway in New York City on Tuesday, May 8, 2018.

Parkinson’s Foundation Adds Alison Herman to its Board of Directors
Tuesday, May 8, 2018

MIAMI – May 9, 2018 – The Parkinson’s Foundation today announced the election of Alison Herman to its board of directors. Herman is senior counsel at Southern Glazer’s Wine & Spirits, a company which has generously supported Parkinson’s Foundation fundraisers.

Statement on Nuplazid Drug
Tuesday, April 10, 2018

On 4/9/18, CNN published an article on the FDA-approved drug, Nuplazid, used to treat hallucinations and psychosis in Parkinson’s disease. The article investigates FDA data showing the number of reported deaths with people taking Nuplazid. Nuplazid was approved by the FDA in 2016 and is manufactured by Acadia Pharmaceuticals.

Parkinson’s Foundation Adds John D. Thomopoulos to its Board of Directors
Monday, March 19, 2018

MIAMI & NEW YORK – March 19, 2018 – The Parkinson’s Foundation today announced the election of John D. Thomopoulos to its board of directors. Thomopoulos is a partner at Ernst & Young.

In Memory of Edythe Kay Marsa
Monday, March 12, 2018

The Parkinson’s Foundation mourns the loss of emeritus board member, Edythe (Edy) Kay Marsa. From 1993 to 2014, she was a member of the Foundation’s board of directors and served on several committees. Edy is survived by her husband William Marsa, who founded the Herbert Kay Parkinson Chapter in honor of her first husband who passed away due to complications from Parkinson’s disease.

Parkinson’s Foundation Announces New Genetic Initiative Connecting Parkinson’s Genetic Data with Clinical Care
Tuesday, March 6, 2018

MIAMI & NEW YORK—March 6, 2018—The Parkinson’s Foundation today announced a new initiative offering genetic testing and counseling to Parkinson’s patients within its Center of Excellence network.

Delegates From The Parkinson’s Community Converge On Capitol Hill To Advocate For Critical Research Funding
Monday, March 5, 2018

—2018 Parkinson’s Policy Forum Co-Sponsored by the Parkinson’s Foundation and the Michael J. Fox Foundation for Parkinson’s Research—

Parkinson’s Foundation Appoints Jena E. Abernathy to Board of Directors
Tuesday, February 27, 2018

MIAMI – February 27, 2018 –  The Parkinson’s Foundation today announced the election of Jena E. Abernathy to its board of directors.

Parkinson’s Foundation Moving Day Walks Fund Local Parkinson’s Programs in Seven Cities for Spring 2018
Friday, February 16, 2018

NEW YORK & MIAMI, FEBRUARY 16, 2018 — The Parkinson’s Foundation is proud to announce that Moving Day, A Walk for Parkinson’s, has funded more than $17 million in mission services to make life better for people living with Parkinson’s disease (PD).

Terranova’s Stephen Bittel Donates $450,000 to Parkinson’s Foundation to Support Expansion of Centers of Excellence Network
Thursday, February 1, 2018

MIAMI – February 1, 2018 – The Parkinson’s Foundation today announced that Stephen Bittel, chairman and founder of Terranova, has made a $450,000 donation to support the expansion of the foundation’s Centers o

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.